Xlife Sciences AG: Listing at Munich stock exchange
Zurich, September 30, 2019
The regional capital Munich offers location advantages for the company and is regarded as the leading biotechnology location in Germany and enjoys a top-notch position in Europe. The location is in particular benefiting from a close networking between academic research and the biotech industry. The majority of biotech companies are spin-offs from scientific institutions. In Munich there have been around 40 start-ups as spin-offs from scientific institutions over the last five years.
End of Media Release
Issuer: Xlife Sciences AG
Key word(s): Finance
30.09.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
|Company:||Xlife Sciences AG|
|Phone:||0041 44 385 84 60|
|Listed:||Regulated Unofficial Market in Munich|
|EQS News ID:||882301|
|End of News||DGAP Media|